ExploreWatchlistsPricing
  1. US-listed companies
  2. BRAINSTORM CELL THERAPEUTICS INC.
  3. Financials
  4. Cash from operations

BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Market cap
$11.03M
P/E ratio
SummaryFinancials
Period EndCash from operations (Million USD)YoY (%)
Dec 31, 2025-7-23.29%
Dec 31, 2024-9-55.55%
Dec 31, 2023-20+5.89%
Dec 31, 2022-19-26.44%
Dec 31, 2021-26-25.37%
Dec 31, 2020-35+212.91%
Dec 31, 2019-11-9.21%
Dec 31, 2018-12+424.03%
Dec 31, 2017-2-59.64%
Dec 31, 2016-6-20.92%
Dec 31, 2015-7+65.10%
Dec 31, 2014-4+10.68%
Dec 31, 2013-4+39.03%
Dec 31, 2012-3+31.17%
Dec 31, 2011-2

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat